Tazobactam is a pharmaceutical drug that inhibits the action of bacterial β-lactamases, especially those belonging to the SHV-1 and TEM groups. It is commonly used as its sodium salt, tazobactam sodium.
Tazobactam is combined with the extended spectrum β-lactam antibiotic piperacillin in the drug piperacillin/tazobactam, used in infections due to Pseudomonas aeruginosa. Tazobactam broadens the spectrum of piperacillin by making it effective against organisms that express β-lactamase and would normally degrade piperacillin.
Tazobactam was patented in 1982 and came into medical use in 1992.
See also
References
Yang Y, Rasmussen BA, Shlaes DM (August 1999). "Class A beta-lactamases--enzyme-inhibitor interactions and resistance". Pharmacology & Therapeutics. 83 (2): 141–151. doi:10.1016/S0163-7258(99)00027-3. PMID 10511459. /wiki/Doi_(identifier) ↩
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 490. ISBN 9783527607495. 9783527607495 ↩